RE:RE:RE:RE:RE:RE:RE:Stepped up their Corporate Presentation GameThese presentations actually are important for insitutional investors, so it is very good they have upped there game. They are listed on NASDAQ and their presentation now is quite comparable to other NASDAQ listed biotechs and no longer looking like it comes from a small Montreal-based company that doesn't know it way very well around Wall Street. You are right that there was no groundbraking new info in the presentation but the conferences they are now presenting at and this presentation are encouraging that when they get their chacne to present to investors who will help move the stock price higher, they will be able to capitalize on that. I also understand they are hopeful to be able to present at more conferences in the weeks ahead so it is good to have this presentation when they do.
Waiting to buy back for general market reasons is fair enough. The market looks like it might be poised to reverse some of the nuttiness of 2020 and no doubt TH would inevitably get caught up in that. Your risk is they announce a partnership on cancer that instantly validates and puts a value on what they have there. It is likely a low risk, but there is some risk of that.
Buying TH right now is hardly a big long term gamble, however. It is just too cheap and even looks oversold on a technical perspective. If even one of their two big opportunities works out, and there is a good chance that will be the case, you will do well even if your entry point was not optimized. If both R&D programs end up looking good, then the stock is going to rocket over the next year. Obviously, there is some chance both R&D programs fail and then the stock is goign to flounder around since the legacy businesses, while cheap at the moment, don't really have any spice in them. The risk then would be the company sells shares at a low price in order to try and pursue growth in another manner.
jfm1330 wrote: I agree it is a better presentation, but I still doubt that this is as important as some think here. We did not learn anything really new in it. You will tell me that it is not every investor that is following the company as closely as we do here, and that now there is an easy to consult document summarazing all the key points about the company. Yes, it's true. But who will go to Thera's website and read it and understand it? Also, I don't think such documents makes a difference for big investors, funds, stuff like that. They have people to do the research on stocks. So basically, this presentation is there to help individual investors interested enough to go to the company's website and search for it, then read it, and understand it enough to be convinced to buy the stock. Call me crazy, but I think I understand this company quite well, and I am still waiting to buy back for general market reasons. Maybe I am wrong and I will miss the train, but I still fear the stock will go lower with a correction in the general market.
I think that what Thera needs is a cascade effect or a domino effect. They need one big investing move from somebody. They need some external validation that will trigger a larger investing movement. They need something that will signal that it is time to jump in. Despite two approved drugs and two very promising programs, I don't feel this urgency to buy right now. That being said, that does not mean it is not the right time to buy. As I said, maybe I will miss a great opportunity by waiting like I do now.